How should ambrisentan-induced pneumonitis be managed?

Ambrisentan-Induced Pneumonitis Management

Immediately discontinue ambrisentan if pneumonitis is suspected, as this is not a recognized adverse effect of ambrisentan and the diagnosis should be reconsidered.

Critical Clarification

Ambrisentan-induced pneumonitis is not documented in the FDA drug label or pulmonary arterial hypertension (PAH) treatment guidelines. The FDA label for ambrisentan 1 lists fluid retention, peripheral edema, decreased hemoglobin, and embryo-fetal toxicity as primary concerns, but pneumonitis is notably absent from warnings and precautions.

Key Diagnostic Considerations

If a patient on ambrisentan presents with respiratory symptoms:

• Reconsider the diagnosis - Pneumonitis is not a recognized adverse effect of ambrisentan
• Evaluate alternative etiologies:
  • Pulmonary veno-occlusive disease (PVOD) - can present with acute pulmonary edema when vasodilators like ambrisentan are initiated 1
  • Fluid retention/decompensated heart failure - a known class effect of endothelin receptor antagonists 1
  • Disease progression of underlying PAH
  • Concomitant medications (if patient is on combination therapy)
  • Infectious causes

If Pneumonitis is Confirmed Despite Ambrisentan Use

Should pneumonitis truly be present (likely from another cause):

1. Stop ambrisentan immediately - Standard practice for any suspected drug-induced lung injury
2. Obtain chest CT - Essential for characterizing infiltrates and excluding other diagnoses
3. Consider bronchoscopy if diagnosis uncertain - May help exclude infection, malignancy, or PVOD
4. Initiate corticosteroids if moderate-to-severe:
   • Prednisone 0.5-1 mg/kg/day orally for grade 2-3 severity
   • Methylprednisolone 1-2 mg/kg/day IV for grade 4 severity
   • Taper over minimum 4-6 weeks to prevent recrudescence
5. Add additional immunosuppression if steroid-refractory after 48 hours:
   • Infliximab, mycophenolate mofetil, or IVIG 2

Monitoring During Ambrisentan Therapy

The FDA-mandated monitoring for ambrisentan focuses on 1:

• Monthly pregnancy tests in females of reproductive potential
• Hemoglobin/hematocrit at baseline, 1 month, then periodically
• Liver function tests monthly (though less hepatotoxic than bosentan)
• Clinical assessment for fluid retention with weight monitoring

Routine chest imaging or pneumonitis surveillance is not indicated for ambrisentan, unlike immune checkpoint inhibitors or certain targeted cancer therapies.

Common Pitfall

Do not confuse ambrisentan's fluid retention and pulmonary edema (particularly in PVOD patients) with drug-induced pneumonitis. These present differently on imaging and require distinct management approaches 1.